ISDA

Entry Detail

PDB ID:

4X8G

Keywords:

Hydrolase/Hydrolase Inhibitor

Title:

Crystal structure of human peptidylarginine deiminase type4 (PAD4) in complex with GSK199

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2014-12-10

Release Date:

2015-01-28

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

3.29 Å

R-Value Free:

0.22

R-Value Work:

0.19

R-Value Observed:

0.20

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Protein-arginine deiminase type-4
Mutations:C645A
Chain IDs:A
Chain Length:671
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q9UM07 Pfam ID:PF08526, PF08527, PF03068 EC:3.5.3.15

Ligand Molecules

3Z0

Primary Citation

Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation.

Lewis, H.D, Liddle, J, Coote, J.E, Atkinson, S.J, Barker, M.D, Bax, B.D, Bicker, K.L, Bingham, R.P, Campbell, M, Chen, Y.H, Chung, C.W, Craggs, P.D, Davis, R.P, Eberhard, D, Joberty, G, Lind, K.E, Locke, K, Maller, C, Martinod, K, Patten, C, Polyakova, O, Rise, C.E, Rudiger, M, Sheppard, R.J, Slade, D.J, Thomas, P, Thorpe, J, Yao, G, Drewes, G, Wagner, D.D, Thompson, P.R, Prinjha, R.K, Wilson, D.M.Show

Nat.Chem.Biol. 11 189 191 (2015)

PMID: 25622091 DOI: 10.1038/nchembio.1735

Abstact

PAD4 has been strongly implicated in the pathogenesis of autoimmune, cardiovascular and oncological diseases through clinical genetics and gene disruption in mice. New selective PAD4 inhibitors binding a calcium-deficient form of the PAD4 enzyme have validated the critical enzymatic role of human and mouse PAD4 in both histone citrullination and neutrophil extracellular trap formation for, to our knowledge, the first time. The therapeutic potential of PAD4 inhibitors can now be explored.

Legend

Protein

Chemical

Disease

Primary Citation of related structures